Almirall stock

ALM · BME · EUR

Compare Almirall
€10.26Change from previous close: +0.39%Absolute change: +€0.04

Close · November 20, 2026

Price history

−18.05% over the period

1 year: from €12.52 (November 20, 2025) to €10.26 (November 20, 2026), −18.05%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€10.26
October 30, 2026€10.60
September 30, 2026€10.56
August 31, 2026€10.32
July 31, 2026€11.10
June 30, 2026€11.26
May 29, 2026€11.38
April 30, 2026€12.58
March 31, 2026€12.16
February 27, 2026€12.88
January 30, 2026€12.62
December 31, 2025€12.84
November 28, 2025€12.64
November 20, 2025€12.52

At a glance

  • The company

    Biopharmaceutical company focused on developing and commercializing treatments for skin diseases and other therapeutic areas

  • Latest results

    Quarter to June 30, 2026 · EPS €0.12 (estimate €0.09)

TickerLandia's take on Almirall

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€9.81
52-wk high€13.98

−26.61% from the 52-week high

Analysts · 11 analysts

Average target€14.28+39.21% vs. price

Buy 10 · Hold 1 · Sell 0 · Strong buy

TickerLandia Fingerprint: Almirall

Compared with similar companies: low profitability, weak momentum, and low price.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Almirall is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Almirall's P/E today is 47.6, above the median of its last 6 fiscal years (33.2; between 25.2 and 173.7 from 2016 to 2025). Almirall's P/E (trailing 12 months): 30.2, +56% against the median of a group of 10 similar companies (19.4).

P/E compared with its history

Compared with 10 similar companies

Almirall's metrics compared with similar companies
MetricAlmirallPosition in the groupBand
P/E (trailing 12 months)30.2High
Forward P/E20.0Middle
Operating margin9.6%Low
ROE4.0%Low
Debt/equity0.18Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Almirall. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€313.23M

Latest quarter · Q2 2026

Net income

€24.25M

Latest quarter · Q2 2026

Quarterly net margin

7.7%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€2.23B
P/E
30.2
EPS
€0.34
Volume
114.85K
Daily trading
€1.64M
Dividend yield
1.82%
Last ex-dividend on May 14, 2026

How Almirall is changing

All results
  • Revenue grew 6.5% a year on average over the last 5 years

  • Operating margin fell from 7.7% to 6.4%

  • Shares outstanding up 19.6% in 5 years

Returns

Almirall returns with dividends

€1,000 invested in Almirall 5 years ago, on November 22, 2021, would be worth €1,091 today with dividends reinvested: +9.08% in total, +1.76% per year. On price alone it would be €994 (−0.58%).

PeriodAlmirallIBEX 35€1,000 becomes
1 month−0.77%−1.15%€992
6 months−9.84%+4.55%€902
Year to date−20.09%+9.04%€799
1 year−16.72%+18.04%€833
3 years+27.36%+91.82%€1,274
5 years+9.08%+113.95%€1,091
10 years−16.54%+119.08%€835

Over the last 6 months it has done better than 10% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. IBEX 35: price only. Calculate your investment

The chart in detail

Almirall: technical analysis

Almirall is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 46.6% below its all-time closing high (€19.22, August 18, 2015).

Trend
Downward
RSI (14 sessions)
42
Between 30 and 70
vs 200-session average
−9.19%

Support and resistance

Price areas where Almirall has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€11.07+7.93%3 touches, last on July 1, 2026
  2. Resistance€10.85+5.72%3 touches, last on September 16, 2026
  3. Resistance€10.52+2.53%7 touches, last on November 9, 2026
  4. Last price€10.26
  5. Support€10.23−0.32%3 touches, last on September 1, 2026
  6. Support€10.03−2.24%2 touches, last on October 28, 2026

Volatility and risk

Over the last year it has moved less than the IBEX 35.

Beta (1 year) vs IBEX 35
0.45
Volatility (60 sessions, annualised)
26.0%
Largest fall in the last year
−28.87%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Almirall: seasonality

Average monthly price change over 20 years

+5.1%Jan+0.7%Feb+0.1%Mar+1.9%Apr+0.7%May−2.2%Jun−1.5%Jul+1.2%Aug−2.2%Sep+1.7%Oct−0.6%Nov−0.7%Dec

Over the last 20 years, the strongest month for Almirall has been January: +5.12% on average, positive in 14 years out of 19. The weakest has been September: −2.19% on average, positive in 12 years out of 20. November, the current month, has been positive in 9 years out of 19 (−0.58% on average).

Show chart data
MonthAverageMedianPositive years
January+5.12%+3.30%14 of 19
February+0.74%+2.06%12 of 19
March+0.09%−2.44%7 of 19
April+1.94%+2.97%11 of 19
May+0.67%+0.42%10 of 19
June−2.15%−1.78%6 of 19
July−1.51%+0.17%10 of 20
August+1.22%−1.26%9 of 20
September−2.19%+0.69%12 of 20
October+1.67%+1.68%12 of 20
November−0.58%−0.86%9 of 19
December−0.70%+0.33%10 of 19

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Almirall and its competitors

Operating from Barcelona since 1943, Almirall develops and sells products focused on skin health, with its main therapeutic emphasis on skin diseases such as psoriasis, atopic dermatitis, acne and actinic keratosis. Its portfolio also covers cardiovascular, respiratory and nervous system medicines. Sales reach Spain, the rest of Europe, the Middle East, the United States, Asia and Africa. The pipeline includes candidates for psoriatic arthritis and pediatric atopic dermatitis, along with earlier-stage programs in hidradenitis suppurativa and alopecia areata.

Headquarters
Barcelona, Spain
Employees
2,108
Founded
1943
Chief executive
Carlos Gallardo Piqué
Almirall and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
AlmirallALM$2.45B9.6%30.2−9.84%
FagronFAGR$1.97B14.3%19.5−0.20%
Siegfried HoldingSFZN$3.4B16.7%16.7−19.46%
Faes FarmaFAE$1.65B13.0%17.9+4.66%
Laboratorios Farmaceuticos RoviROVI$3.68B20.2%16.0+5.25%
PharmaNutraPHN$917.61M22.0%36.7−2.50%

Same industry or related industries, similar size. Compare Almirall with its competitors · Full profile